ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Clinical Cancer Research|2025Cited by 19
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple MyelomaSagar Lonial, Shaji Kumar, Stefano Tarantolo et al.|Blood|2021Cited by 3
Supplementary Table S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0
Supplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0